Smart scans could spare lymphoma patients from extra chemo

NCT ID NCT03758989

Recruiting now Knowledge-focused Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether PET scans and blood tests for tumor DNA can help doctors adjust chemotherapy for people with early-stage diffuse large B-cell lymphoma (DLBCL). About 40 participants will receive standard R-CHOP treatment, and their response will be monitored with imaging and blood tests. The goal is to see if these tools can identify who needs less or more treatment, potentially reducing side effects while maintaining effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP)
What this could lead to: If successful, this could lead to more personalized treatment for early-stage DLBCL, reducing unnecessary chemotherapy and side effects.
What could go wrong: This is a small, early-phase study (40 participants) focused on monitoring, not a new treatment. The approach may not improve outcomes or be widely applicable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma Richter transformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DLBCL

Contacts and locations

Locations

University of Rochester
RECRUITING

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.